CN101754688A - 糖基化乳及其用途 - Google Patents
糖基化乳及其用途 Download PDFInfo
- Publication number
- CN101754688A CN101754688A CN200880013641A CN200880013641A CN101754688A CN 101754688 A CN101754688 A CN 101754688A CN 200880013641 A CN200880013641 A CN 200880013641A CN 200880013641 A CN200880013641 A CN 200880013641A CN 101754688 A CN101754688 A CN 101754688A
- Authority
- CN
- China
- Prior art keywords
- product
- glycosylation
- glycosylated
- hypnosis
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013336 milk Nutrition 0.000 title claims abstract description 27
- 210000004080 milk Anatomy 0.000 title claims abstract description 27
- 239000008267 milk Substances 0.000 title claims abstract description 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 58
- 108010076119 Caseins Proteins 0.000 claims abstract description 36
- 102000011632 Caseins Human genes 0.000 claims abstract description 32
- 241000283690 Bos taurus Species 0.000 claims abstract description 29
- 235000021247 β-casein Nutrition 0.000 claims abstract description 25
- 230000007062 hydrolysis Effects 0.000 claims abstract description 17
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 17
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 13
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 10
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 10
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 10
- 241000124008 Mammalia Species 0.000 claims abstract description 9
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 7
- 230000013595 glycosylation Effects 0.000 claims description 74
- 238000006206 glycosylation reaction Methods 0.000 claims description 73
- 210000000481 breast Anatomy 0.000 claims description 44
- 230000000147 hypnotic effect Effects 0.000 claims description 43
- 101800005209 Deltorphin Proteins 0.000 claims description 30
- BHSURCCZOBVHJJ-NWOHMYAQSA-N Deltorphin A Chemical compound C([C@H](N)C(=O)N[C@H](CCSC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(N)=O)C1=CC=C(O)C=C1 BHSURCCZOBVHJJ-NWOHMYAQSA-N 0.000 claims description 30
- 238000002360 preparation method Methods 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 10
- 235000013361 beverage Nutrition 0.000 claims description 10
- 239000008103 glucose Substances 0.000 claims description 10
- 108091005608 glycosylated proteins Proteins 0.000 claims description 10
- 102000035122 glycosylated proteins Human genes 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 9
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 7
- 235000020247 cow milk Nutrition 0.000 claims description 7
- 229930091371 Fructose Natural products 0.000 claims description 6
- 239000005715 Fructose Substances 0.000 claims description 6
- 229940126534 drug product Drugs 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 2
- -1 galactolipin Chemical compound 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 230000002035 prolonged effect Effects 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 10
- 235000014633 carbohydrates Nutrition 0.000 abstract description 5
- 230000036252 glycation Effects 0.000 abstract description 4
- 238000005259 measurement Methods 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 235000018102 proteins Nutrition 0.000 abstract description 3
- 108090000623 proteins and genes Proteins 0.000 abstract description 3
- 102000004169 proteins and genes Human genes 0.000 abstract description 3
- 108700028369 Alleles Proteins 0.000 abstract description 2
- 230000002557 soporific effect Effects 0.000 abstract 2
- RKYJTDSQXOMDAD-JKXTZXEVSA-N (2s,3s)-2-[[(2s)-1-[2-[[(2s)-1-[(2s)-2-[[(2s)-1-[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoic acid Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H]1N(C(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CC=2C=CC(O)=CC=2)CCC1 RKYJTDSQXOMDAD-JKXTZXEVSA-N 0.000 abstract 1
- 102000014171 Milk Proteins Human genes 0.000 abstract 1
- 108010011756 Milk Proteins Proteins 0.000 abstract 1
- 108010020546 beta-casomorphin 7 Proteins 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000021239 milk protein Nutrition 0.000 abstract 1
- 239000000047 product Substances 0.000 description 48
- 230000000694 effects Effects 0.000 description 13
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 10
- 230000002255 enzymatic effect Effects 0.000 description 10
- 230000029087 digestion Effects 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 239000005018 casein Substances 0.000 description 7
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 7
- 235000021240 caseins Nutrition 0.000 description 7
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 230000006862 enzymatic digestion Effects 0.000 description 6
- 229960002737 fructose Drugs 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 229960005181 morphine Drugs 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 101150008391 A1 gene Proteins 0.000 description 4
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 210000004498 neuroglial cell Anatomy 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 230000007071 enzymatic hydrolysis Effects 0.000 description 3
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 238000009928 pasteurization Methods 0.000 description 3
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 2
- RRUYWEMUWIRRNB-LURJTMIESA-N (2s)-6-amino-2-[carboxy(methyl)amino]hexanoic acid Chemical compound OC(=O)N(C)[C@H](C(O)=O)CCCCN RRUYWEMUWIRRNB-LURJTMIESA-N 0.000 description 2
- 101150109698 A2 gene Proteins 0.000 description 2
- 206010048799 Acute generalised exanthematous pustulosis Diseases 0.000 description 2
- 208000005441 Acute generalized exanthematous pustulosis Diseases 0.000 description 2
- 108090000317 Chymotrypsin Proteins 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 108010059378 Endopeptidases Proteins 0.000 description 2
- 102000005593 Endopeptidases Human genes 0.000 description 2
- 108010091443 Exopeptidases Proteins 0.000 description 2
- 102000018389 Exopeptidases Human genes 0.000 description 2
- 241000209219 Hordeum Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000002262 Schiff base Substances 0.000 description 2
- 150000004753 Schiff bases Chemical class 0.000 description 2
- 208000032140 Sleepiness Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 210000002318 cardia Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 235000020185 raw untreated milk Nutrition 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 230000037321 sleepiness Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 229960004799 tryptophan Drugs 0.000 description 2
- YQHPCDPFXQXCMV-VIFPVBQESA-N (2s)-2-amino-6-[[2-(furan-2-yl)-2-oxoethyl]amino]hexanoic acid Chemical compound OC(=O)[C@@H](N)CCCCNCC(=O)C1=CC=CO1 YQHPCDPFXQXCMV-VIFPVBQESA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241001674044 Blattodea Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- ZOEGQXCAXOUFHN-UHFFFAOYSA-N Furosin Natural products OC1C2OC(=O)C(C=3C4C5(O)O)=CC(O)=C(O)C=3OC5(O)C(=O)C=C4C(=O)OC1C(CO)OC2OC(=O)C1=CC(O)=C(O)C(O)=C1 ZOEGQXCAXOUFHN-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000009793 Milk Hypersensitivity Diseases 0.000 description 1
- 201000010859 Milk allergy Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010030544 Peptidyl-Lys metalloendopeptidase Proteins 0.000 description 1
- 208000016542 Progressive myoclonic epilepsy with dystonia Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108091007464 S-glycosylated proteins Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- FRYDSOYOHWGSMD-UHFFFAOYSA-N [C].O Chemical compound [C].O FRYDSOYOHWGSMD-UHFFFAOYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000009924 canning Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229940021722 caseins Drugs 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000517 effect on sleep Effects 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 102000051367 mu Opioid Receptors Human genes 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 108020001612 μ-opioid receptors Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Animal Husbandry (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Anesthesiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Dairy Products (AREA)
- Feed For Specific Animals (AREA)
Abstract
Description
阶段 | 温度 | pH |
所接受的原料乳 | 16C | 6.82 |
添加柠檬酸盐之后 | 15.8℃ | 6.74 |
添加抗坏血酸之后 | 15℃ | 6.64 |
均质之后 | 6.73 | |
UHT处理之后 | 17.2℃ | 6.42 |
样品 | 糠氨酸mg/ml | FAST指数 | CML ng/ml |
原料乳 | 4.4 | - | - |
巴氏杀菌乳 | 9.5 | 10 | 2.9 |
含抗坏血酸的巴氏杀菌乳(1g/升) | - | 19.3 | - |
UHT乳 | 20.5 | 17.5 | - |
“睡眠乳”(本发明) | 22 | 22.5 | 5.91 |
Claims (13)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ55474707 | 2007-04-24 | ||
NZ554747 | 2007-04-24 | ||
PCT/NZ2008/000092 WO2008130255A1 (en) | 2007-04-24 | 2008-04-24 | Glycated milk and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101754688A true CN101754688A (zh) | 2010-06-23 |
Family
ID=39875700
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880013641A Pending CN101754688A (zh) | 2007-04-24 | 2008-04-24 | 糖基化乳及其用途 |
Country Status (13)
Country | Link |
---|---|
US (2) | US20100130406A1 (zh) |
EP (1) | EP2146583A4 (zh) |
JP (1) | JP2010524497A (zh) |
KR (1) | KR20100017337A (zh) |
CN (1) | CN101754688A (zh) |
AU (1) | AU2008241637B2 (zh) |
BR (1) | BRPI0810812A2 (zh) |
CA (1) | CA2685005A1 (zh) |
MX (1) | MX2009011525A (zh) |
MY (1) | MY158084A (zh) |
NZ (1) | NZ580681A (zh) |
RU (1) | RU2009140481A (zh) |
WO (1) | WO2008130255A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103843904A (zh) * | 2014-02-18 | 2014-06-11 | 黑龙江省乳品工业技术开发中心 | 一种牛羊乳混合饮料及其制备方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016082961A (ja) * | 2014-10-28 | 2016-05-19 | 株式会社近藤榮一商店 | 睡眠誘導牛乳とその製造方法および乳牛用飼料 |
CN112868792A (zh) * | 2019-11-29 | 2021-06-01 | 内蒙古蒙牛乳业(集团)股份有限公司 | 液态乳制品及其制备方法 |
US20230105668A1 (en) * | 2020-03-26 | 2023-04-06 | Cargill, Incorporated | Microprocessing for preparing modified protein |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07116234B2 (ja) * | 1985-06-04 | 1995-12-13 | 味の素株式会社 | 新規ペプチド |
ATE442585T1 (de) * | 1994-11-04 | 2009-09-15 | A2 Corp Ltd | Selektionsverfahren für nicht-diabetogene milch oder milchprodukte sowie hierdurch erfasste milch oder milchprodukte |
US7803764B2 (en) * | 2004-03-29 | 2010-09-28 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Amphipathic glycopeptides |
-
2008
- 2008-04-24 JP JP2010506108A patent/JP2010524497A/ja active Pending
- 2008-04-24 US US12/597,421 patent/US20100130406A1/en not_active Abandoned
- 2008-04-24 RU RU2009140481/10A patent/RU2009140481A/ru not_active Application Discontinuation
- 2008-04-24 WO PCT/NZ2008/000092 patent/WO2008130255A1/en active Application Filing
- 2008-04-24 AU AU2008241637A patent/AU2008241637B2/en active Active
- 2008-04-24 CA CA002685005A patent/CA2685005A1/en not_active Abandoned
- 2008-04-24 CN CN200880013641A patent/CN101754688A/zh active Pending
- 2008-04-24 EP EP08753853A patent/EP2146583A4/en not_active Withdrawn
- 2008-04-24 BR BRPI0810812A patent/BRPI0810812A2/pt not_active IP Right Cessation
- 2008-04-24 MX MX2009011525A patent/MX2009011525A/es not_active Application Discontinuation
- 2008-04-24 MY MYPI20094453A patent/MY158084A/en unknown
- 2008-04-24 NZ NZ580681A patent/NZ580681A/xx unknown
- 2008-04-24 KR KR1020097024505A patent/KR20100017337A/ko not_active Application Discontinuation
-
2013
- 2013-08-29 US US14/014,089 patent/US20140010764A1/en not_active Abandoned
Non-Patent Citations (3)
Title |
---|
ANNUNZIATA LAPOLLA,等: "Enzymatic Digestion and Mass Spectrometry in the Study of Advanced Glycation End Products/Peptides", 《J AM SOC MASS SPECTROM》 * |
R.B. ELLIOTT: "Diabetes – A man made disease", 《MEDICAL HYPOTHESES》 * |
党国华,等: "乳源β-酪啡肽的生理功能及应用前景", 《饲料博览》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103843904A (zh) * | 2014-02-18 | 2014-06-11 | 黑龙江省乳品工业技术开发中心 | 一种牛羊乳混合饮料及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
AU2008241637B2 (en) | 2013-03-14 |
MX2009011525A (es) | 2010-02-11 |
US20100130406A1 (en) | 2010-05-27 |
MY158084A (en) | 2016-08-30 |
CA2685005A1 (en) | 2008-10-30 |
EP2146583A4 (en) | 2010-04-14 |
BRPI0810812A2 (pt) | 2016-07-26 |
JP2010524497A (ja) | 2010-07-22 |
KR20100017337A (ko) | 2010-02-16 |
RU2009140481A (ru) | 2011-05-27 |
NZ580681A (en) | 2012-12-21 |
AU2008241637A1 (en) | 2008-10-30 |
EP2146583A1 (en) | 2010-01-27 |
US20140010764A1 (en) | 2014-01-09 |
WO2008130255A1 (en) | 2008-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Darewicz et al. | The preventive potential of milk and colostrum proteins and protein fragments | |
EP2274002B1 (en) | Leucine-rich peptide compositions and methods for isolation | |
CN106983854A (zh) | 用于苯丙酮尿症和其他代谢疾病的营养控制的糖巨肽药用食物 | |
Faist et al. | Determination of lysinoalanine in foods containing milk protein by high-performance chromatography after derivatisation with dansyl chloride | |
US20110263505A1 (en) | Whey Protein Hydrolysate Containing Tryptophan Peptide Consisting of Alpha Lactalbumin and the Use Thereof | |
JP6524176B2 (ja) | プロリルオリゴペプチダーゼ阻害剤 | |
CN101754688A (zh) | 糖基化乳及其用途 | |
WO2017010538A1 (ja) | 動植物由来ペプチド含有血清カルノシン分解酵素阻害用組成物 | |
Jarmołowska et al. | Serum activity of dipeptidyl peptidase IV (DPPIV; EC 3.4. 14.5) in breast-fed infants with symptoms of allergy | |
JP5118915B2 (ja) | 褥瘡改善剤 | |
Alu'datt et al. | Characterization and biological properties of peptides isolated from dried fermented cow milk products by RP‐HPLC: Amino acid composition, antioxidant, antihypertensive, and antidiabetic properties | |
US20090012001A1 (en) | Lipid metabolism-improving agent | |
Dixon et al. | Disorders of carbohydrate metabolism | |
JP2017006030A (ja) | アミノ酸を原料とする嗜好性と保健的機能性に優れた素材、およびこれを利用した食品・ペットフード | |
EP4317173A1 (en) | Peptide and composition containing peptide as active ingredient | |
CN1317979C (zh) | 改良的富含甲硫氨酸的食品和它们的制造方法 | |
EP3753569A1 (en) | Composition for reducing blood pressure and/or for reducing neutral fats | |
WO2020013306A1 (ja) | 注意機能および判断機能向上用組成物 | |
JP2020097535A (ja) | 血圧を降下させるための組成物 | |
CN101115497A (zh) | 预防生活习惯病的食品 | |
JP7511056B2 (ja) | 脳血流を増加させるための組成物 | |
JP2001069949A (ja) | 豚肉分解物及びそれを含有する食品 | |
AU2008257720A1 (en) | Foods and beverages lacking glycation products | |
JP2017169451A (ja) | 睡眠誘導牛乳とその製造方法および乳牛用飼料 | |
KR20210038927A (ko) | 단기간 신장 기능을 위한 단백질 가수분해물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160727 Address after: Oakland, New Zealand Applicant after: NIG nutrition Ltd. Address before: Oakland, New Zealand Applicant before: New image International Ltd. Effective date of registration: 20160727 Address after: Oakland, New Zealand Applicant after: New image International Ltd. Address before: Oakland, New Zealand Applicant before: Somnaceutics Ltd. |
|
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20100623 |
|
RJ01 | Rejection of invention patent application after publication |